Outcomes of patients aged 60-75 years with favorable-risk, NPM1 mutated AML are similar between intensive and less intense regimens. Patients who underwent alloHCT had excellent outcomes, regardless of their first-line treatment regimen. Read here: ow.ly/8eNg50X8Ita

How can #RealWorldEvidence drive innovation in #SickleCell Disease? A new Blood Journals Portfolio manuscript details the evolving role of the ASH RC Data Hub as a strategic registry network—backed by curation & QC processes. 🔍 Explore the data: ow.ly/b6Yp50Xb9gA #RWE

Explore our portfolio - today featuring Blood RCI! 🩸 This journal is supported by expert editors in their field, Dr. Patrick Gallagher, Editor-in-Chief, and Dr. Laura Silvestri, Deputy Editor. Read more about it and the submissions they're looking for: ow.ly/TCu450XbcPz

Immune cells display an abnormal maturation and a proinflammatory profile in telomere biology disorders [Sep 24, 2025] Gomes et al. Blood Advances Blood Journals Portfolio ashpublications.org/bloodadvances/… #ImmunoOnc

Malignant plasma cells form spatially segregated microenvironments with distinct transcriptional profiles and cell composition. Read the full piece in Blood: ow.ly/3Pf350Xbe2J

This study reveals an unexpected role for plasminogen as a carrier of small non-coding RNAs (SNRAs) that modulate both its enzymatic and immunogenic activities. Read the full article in Blood: ow.ly/ZbCk50X9rIA

Patients with TBDs display decreased thymic output, abnormal maturation, skewed cell diversity, activation, and exhaustion of lymphocytes. Read the full article in Blood Advances: ow.ly/9RXx50XbKpg

Distinct, induced Ras pathway lesions share shunting to myeloid lineages but have opposing effects on HSCs. Strong oncogenic Ras signals are incompatible with a metabolically quiescent state of HSCs and progenitor cells. Read in Blood Advances: ow.ly/kIb250XbKxS

Colon cancer reprograms tryptophan metabolism to augment VTE risk in mice, which is mitigated by an IDO1 inhibitor. Read in Blood Advances: ow.ly/hgTf50XbOVN

Real-world outcomes of multiple myeloma in a resource-constrained setting: a 14-year experience from a tertiary cancer center in Jordan. Read in Blood Global Hematology: ow.ly/vWZr50XbRM7

A substantial depletion of bone marrow B-cell progenitor populations occurs after long-term broad-spectrum antibiotic therapy. Read the full article in Blood Advances: ow.ly/45Wi50XbKBi

Responses were seen in patients with MDS, suggesting that dose optimization / combination therapy is necessary in AML. Read in Blood Neoplasia: ow.ly/RU5c50XbPbZ

The combination of crizotinib and BH3 mimetic drugs is synergistic in ALK+ ALCL and overcomes the protection mediated by stromal cells. Read in Blood Advances: ow.ly/Nw5H50XbNAQ

GPX4 regulates lipid hydroperoxide levels, protecting stored human and mouse RBCs from ferroptosis. Read in Blood RCI: ow.ly/O31Y50XbQ8o

Explore 'Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti PD-1 refractory Hodgkin lymphoma'. Results suggest favezelimab contributed to the efficacy observed with favezelimab plus pembrolizumab in MK-4280-003: ow.ly/Rf9P50XbNY7

Hodgkin lymphoma treatment patterns and outcome disparities in low and middle-income countries. Read in Blood Global Hematology: ow.ly/hwNt50XbS3F

Targeted deletion of Il6 in MSCs intensifies the cytotoxicity of Ara-C against AML and prolongs overall survival. Read the full piece in Blood Advances: ow.ly/7mvn50XbO7a

Red cell physiologic stress results in lower quality transfusions: a randomized trial in adults with sickle cell disease. Read in Blood RCI ow.ly/g5KI50XbQAW #SCD #SickleCellDisease

Want to amplify your research? Submit to the Blood Journals Portfolio—renowned across hematology for rapid publication, global reach, and trusted impact! 🩸 Learn more: ow.ly/Qasn50XcHgY #BloodJournalsPortfolio #Hematology #GetPublished